HBC recorded total operating revenues of NOK 68.4 million in the second quarter of 2025, compared to NOK 80.4 million in the same period last year. Net operating revenues were NOK 67.8 million, compared to NOK 72.2 million in the same quarter last year. Total operating revenue for the first six months of 2025 was NOK 129.3 million (NOK 132.8 million).
EBITDA for the quarter was negative NOK 5.4 million, compared to NOK -2.0 million in Q2 2024. The first six months was negative NOK 25.3 million (NOK-18.2 million) The Operational EBITDA* amounted to positive NOK 1.3 million, compared to negative NOK 2.5 million same quarter last year, reflecting the exclusion of non-recurring items such as restructuring costs (NOK 0.0 million), clinical trial and R&D investments (NOK 4.9 million), and Berkåk project costs (NOK 2.4 million). For the first six months the Operational EBITDA* amounted to NOK -7.0 million (NOK-10.3 million).
Cash and cash equivalents decreased by NOK 3.9 million during the quarter, reaching NOK 68.0 million at the end of Q2 2025, up from NOK 25.3 million a year earlier. Including available credit lines, total liquidity ended at NOK 76.5 million as of 30 June, 2025.
Highlights in the second quarter:
- Human Nutrition B2B Sales increased 180% YoY to NOK 9.3m, driven by strong demand in Europe, China, and Southeast Asia. OmeGo® and ProGo® …